NDA 213218 · Sarfe Pharms
Soaanz
Torsemide · Oral · Loop Diuretic
Last checked: Nov 20, 2026Latest source record: Nov 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 14, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
44
8 Phase 3, 3 recruiting
FAERS reports
33,936
27,263 serious, 4,525 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 9, 2026.
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- SOAANZ · TORSEMIDE 60MG · TABLET, ORAL · Discontinued
- SOAANZ · TORSEMIDE 40MG · TABLET, ORAL · Prescription
- SOAANZ · TORSEMIDE 20MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Torsemide" as an intervention, any sponsor and status, largest first.
- Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of ChronotherapyPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00295542 · 3,344 participants · Start Mar 2000 · Primary completion Apr 2009
Drug: ACEI (including spirapril, enalapril, quinapril, lisinopril); ARB (including valsartan, telmisartan, olmesartan) and 2 more · For: Hypertension
Sites: Santiago de Compostela, Spain
- TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart FailurePivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03296813 · 2,973 participants · Start Jul 11, 2018 · Primary completion Jul 29, 2022
Drug: Torsemide; Furosemide · For: Heart Failure
Sites: Alexander City, Alabama; Huntsville, Alabama; Tucson, Arizona · 60 sites in all
- Optimal Medical Treatment of Difficult-to-treat HypertensionPivotal-lookingStatus unknown
National Institute of Cardiology, Warsaw, PolandAcademic, hospital or other
NCT06275763 · 2,500 participants (planned) · Start Oct 20, 2023 · Primary completion Dec 1, 2025
Drug: Phase C: Eplerenone; Phase C: Spironolactone and 2 more · For: Hypertension
Sites: Warsaw, Poland
- Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.Pivotal-lookingCompleted
Ferrer Internacional S.A.Industry
NCT00334386 · 388 participants · Start Apr 2005
Drug: Torasemide Prolonged Release (loop diuretic); Torasemide Immediate Release (loop diuretic) · For: Hypertension
NHS Greater Glasgow and ClydeAcademic, hospital or other
NCT03354897 · 228 participants · Start Apr 5, 2017 · Primary completion Oct 30, 2021
Drug: Torasemide 5Mg Tablet · For: Cardiovascular Diseases; Hypertension
Sites: Glasgow, United Kingdom
Matthias SchwabAcademic, hospital or other
NCT01788254 · 144 participants · Start Jan 2012 · Primary completion May 2015
Drug: Codeine; Midazolam and 3 more · For: Genotype-related Drug Metabolism
Sites: Stuttgart, Germany; Tübingen, Germany
- ToRsemide for pOstpartum HYpertensionPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT02813551 · 118 participants · Start Aug 2016 · Primary completion Jul 28, 2017
Drug: Torsemide; Placebo · For: Preeclampsia
Sites: Houston, Texas
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHAcademic, hospital or other
NCT01845194 · 117 participants · Start Dec 2009 · Primary completion Oct 2013
Drug: Codeine; Midazolam and 5 more · For: Drug Biotransformation; Membrane Transport
Sites: Göttingen, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea3,621
- fatigue2,261
- diarrhoea2,143
- nausea2,119
- dizziness2,004
- acute kidney injury1,817
- death1,768
- general physical health deterioration1,689
- fall1,676
- oedema peripheral1,628
- headache1,597
- hypotension1,545
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 282 |
| 2006 | 323 |
| 2007 | 327 |
| 2008 | 410 |
| 2009 | 521 |
| 2010 | 572 |
| 2011 | 821 |
| 2012 | 975 |
| 2013 | 404 |
| 2014 | 550 |
| 2015 | 848 |
| 2016 | 1,256 |
| 2017 | 1,175 |
| 2018 | 1,481 |
| 2019 | 1,745 |
| 2020 | 1,934 |
| 2021 | 2,830 |
| 2022 | 4,327 |
| 2023 | 3,026 |
| 2024 | 3,598 |
| 2025 | 3,685 |
| 2026 | 2,622 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Soaanz (Torsemide)
2024 spending
$5.2M
Beneficiaries
5,342
12,012 claims
Per beneficiary
$965
$9.27 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $1,329,075 |
| 2023 | $4,786,854 |
| 2024 | $5,153,740 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Mentz RJ, Anstrom KJ, Eisenstein EL, et al. · JAMA 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Postpartum Diuretics for Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis.
Trawick Roberts E, Quist-Nelson J, Brotkin EJ, et al. · Obstet Gynecol 2025 · Systematic Review, Meta-Analysis
- Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.
Abraham B, Megaly M, Sous M, et al. · Am J Cardiol 2020 · Meta-Analysis, Systematic Review
- Clinical Outcomes With Furosemide Versus Torsemide in Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis.
Siddiqi AK, Javaid H, Ahmed M, et al. · Curr Probl Cardiol 2023 · Meta-Analysis, Systematic Review
- Should torsemide be the loop diuretic of choice in systolic heart failure?
DiNicolantonio JJ · Future Cardiol 2012 · Meta-Analysis, Systematic Review
- Loop diuretics for patients receiving blood transfusions.
Sarai M, Tejani AM · Cochrane Database Syst Rev 2015 · Meta-Analysis, Systematic Review
Sponsor: Sarfe Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.